NBIX241115P210000
- 0.00
- 0.000.00%
Neurocrine Biosciences Newsroom
Express News | Neurocrine Biosciences Inc : BMO Raises Target Price to $121 From $114
Morgan Stanley Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Maintains Target Price $170
Evercore Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Cuts Target Price to $175
A Quick Look at Today's Ratings for Neurocrine Biosciences(NBIX.US), With a Forecast Between $136 to $192
Neurocrine Biosciences Analyst Ratings
Decoding Neurocrine Biosciences Inc (NBIX): A Strategic SWOT Insight
Neurocrine Biosciences, Inc. (NBIX) Q3 2024 Earnings Call Transcript Summary
Neurocrine Biosciences Lifts FY24 INGREZZA Sales View, Plans $300 Mln Buyback; Stock Up - Update
Needham Reiterates Hold on Neurocrine Biosciences
Neurocrine Biosciences Inc Q3 Profit Increases, Beats Estimates
Neurocrine Biosciences Shares Are Trading Higher After the Company Reported Better-than-expected Q3 Financial Results and Raised Annual Valbenazine Revenue Outlook. It Also Authorized $300 Million Stock Buyback.
Earnings Flash (NBIX) NEUROCRINE BIOSCIENCES Reports Q3 Revenue $622.1M
Neurocrine Biosciences Raises FY24 Net Product (Valbenazine) Revenue Outlook To $2.30B-$2.32B
Neurocrine Biosciences Bats Q3 Revenue Estimates, Revises Guidance
Neurocrine Biosciences | 10-Q: Q3 2024 Earnings Report
Neurocrine Biosciences Board Authorizes $300M Stock Buyback
Express News | Neurocrine Biosciences Inc - Board Authorizes $300 Mln Share Repurchase Plan
Express News | Neurocrine Biosciences Reports Third Quarter 2024 Financial Results and Raises 2024 Ingrezza Sales Guidance
Express News | Neurocrine Biosciences Q3 Product Sales USD 616.6 Million
Express News | Neurocrine Biosciences Q3 Adjusted EPS USD 1.81 Vs. IBES Estimate USD 1.51